Prioritis at Pricing & Market Access Amsterdam
Prioritis will be present at the Pharma Pricing & Market Access Congress Amsterdam, March 19th - 20th 2019 Stand 28 We are proud to...
18
Feb
05
Nov
Prioritis at ISPOR Barcelona – Stand 201
Prioritis is looking forward to seeing you at ISPOR Europe 2018. Barcelona, 12-14 November Stand 201 We are proud to introduce a year...
09
Oct
Japanese decisions in Prismaccess and Evalumade
Prioritis is pleased to announce the incorporation of Japanese reimbursement, price and access decisions in Prismaccess and Evalumade. Japan is the...
05
Jul
Drug Reimbursement and Pricing Policy in Taiwan
Healthcare need already outstrips offer in Asia–Pacific and the gap will grow with continued increases in income, population, disease burdens,...
30
May
FDA wishes faster approval for gene therapies
FDA wishes to speed approval for new therapies aimed at diseases caused by defective genes. Gene therapies are meant to be...
14
May
Prioritis at ISPOR Baltimore
ISPOR 23rd Annual International Meeting is almost here and Prioritis is happy to announce it’s first participation in Baltimore! Our International...
13
Mar
Prioritis at Pharma Pricing and Market Access congress London
Prioritis will be present at the Pharma Pricing & Market Access Congress EU 2018. The congress will take place at the...
26
Feb
Spain, a new financing model for high economic-impact medicines
The Dirección de la Cartera Básica de Servicios del SNS y Farmacia, has announced the start-up of a new financing...
19
Feb
Prismaccess’ data in an international study in oncology
An international study, conducted by the French National Cancer Institute (INCa), uses information from the Prismaccess and Evalumade databases. Its...
14
Feb
2018, innovations and new economic models
Blockbuster drugs losing patent protection, significant advancements in innovation and major financial issues, the year to come will be fundamental. In...
- 1
- 2